CureVac/$CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CureVac
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
$CVAC
Sector
Primary listing
Employees
904
Headquarters
Website
CureVac Metrics
BasicAdvanced
$1.2B
5.31
$1.01
2.53
-
Price and volume
Market cap
$1.2B
Beta
2.53
52-week high
$5.72
52-week low
$2.37
Average daily volume
595K
Financial strength
Current ratio
6.172
Quick ratio
5.887
Long term debt to equity
5.312
Total debt to equity
6.145
Interest coverage (TTM)
589.30%
Profitability
EBITDA (TTM)
291.761
Gross margin (TTM)
94.85%
Net profit margin (TTM)
37.93%
Operating margin (TTM)
46.40%
Effective tax rate (TTM)
12.14%
Revenue per employee (TTM)
$657,040
Management effectiveness
Return on assets (TTM)
23.77%
Return on equity (TTM)
40.22%
Valuation
Price to earnings (TTM)
5.313
Price to revenue (TTM)
2.004
Price to book
2.05
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
5.216
Free cash flow yield (TTM)
19.17%
Free cash flow per share (TTM)
1.024
Growth
Revenue change (TTM)
675.15%
Earnings per share change (TTM)
-168.74%
3-year revenue growth (CAGR)
64.31%
3-year earnings per share growth (CAGR)
-9.85%
What the Analysts think about CureVac
Analyst ratings (Buy, Hold, Sell) for CureVac stock.
Bulls say / Bears say
The European Investment Bank and European Commission provided a €75 million loan through the Horizon 2020 Infectious Diseases Finance Facility to finalize CureVac’s new mRNA facility in Tübingen, enhancing its manufacturing capabilities (Reuters)
BioNTech agreed to acquire CureVac in a $1.25 billion all-stock transaction, offering approximately $5.46 in BioNTech ADS for each CureVac share, which provides immediate value and liquidity to CureVac shareholders (Reuters)
The deal includes a collar structure, giving CureVac investors extra upside if BioNTech ADS trade above $126.55, linking their potential gains to BioNTech’s expanding oncology pipeline (Reuters)
BioNTech filed a motion in January 2025 to invalidate a key European mRNA patent held by CureVac in Germany, jeopardizing its intellectual property protection and potentially weakening its competitive edge (Reuters)
CureVac reached a settlement in August 2025 to resolve a longstanding mRNA patent dispute with Pfizer and BioNTech, agreeing to pay $740 million upfront plus royalties, which highlights previous infringement concerns and ongoing royalty costs that could squeeze future margins (Reuters)
CureVac posted a net loss of $260.2 million and negative operating cash flow of $267.9 million in 2023, reflecting continuing unprofitable results and dependence on external financing to support operations (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
CureVac Financial Performance
Revenues and expenses
CureVac Earnings Performance
Company profitability
CureVac News
AllArticlesVideos
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
Accesswire1 month ago
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
Proactive Investors1 month ago
CureVac settles patent dispute litigation with Pfizer and BioNTech
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $1.2B as of September 15, 2025.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 5.31 as of September 15, 2025.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.